10x Genomics, Inc. (TXG) Operating Margin
- Operating margin · 12 months: Value -14.33%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -14.33% | Operating income / revenue. Period ending 2026-06-30. $-88.38M ÷ $616.91M × 100 ≈ -14.33% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -88.38M USD | Operating Income (Loss) |
| Revenue | 616.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | 297.01M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-88.38M | $616.91M | (m) | (m) | $297.01M | -14.33% |
| 2026-03-31 | $-38.70M | $638.78M | (m) | (m) | $292.78M | -6.06% |
| 2025-12-31 | $-60.98M | $642.82M | (m) | (m) | $316.13M | -9.49% |
| 2025-09-30 | $-91.28M | $641.81M | (m) | (m) | $333.34M | -14.22% |
| 2025-06-30 | $-100.53M | $644.47M | (m) | (m) | $339.69M | -15.60% |
| 2025-03-31 | $-172.39M | $624.66M | (m) | (m) | $348.30M | -27.60% |
| 2024-12-31 | $-194.56M | $610.78M | (m) | (m) | $344.34M | -31.85% |
| 2024-09-30 | $-199.91M | $629.74M | (m) | (m) | $336.64M | -31.74% |
| 2024-06-30 | $-253.22M | $631.73M | (m) | (m) | $337.35M | -40.08% |
| 2024-03-31 | $-274.84M | $625.45M | (m) | (m) | $345.82M | -43.94% |
| 2023-12-31 | $-265.33M | $618.73M | (m) | (m) | $343.33M | -42.88% |
| 2023-09-30 | $-233.24M | $590.98M | (m) | (m) | $336.09M | -39.47% |
| 2023-06-30 | $-178.44M | $568.41M | (m) | (m) | $327.08M | -31.39% |
| 2023-03-31 | $-178.20M | $536.20M | (m) | (m) | $314.90M | -33.23% |
| 2022-12-31 | $-167.94M | $516.41M | (m) | (m) | $298.30M | -32.52% |
| 2022-09-30 | $-160.68M | $503.71M | (m) | (m) | $289.29M | -31.90% |
| 2022-06-30 | $-136.56M | $497.93M | (m) | (m) | $277.96M | -27.43% |
| 2022-03-31 | $-83.77M | $499.17M | (m) | (m) | $267.33M | -16.78% |
| 2021-12-31 | $-52.25M | $490.49M | (m) | (m) | $257.56M | -10.65% |
| 2021-09-30 | $-446.01M | $459.18M | (m) | (m) | $243.66M | -97.13% |
| 2021-06-30 | $-495.38M | $405.70M | (m) | (m) | $233.13M | -122.11% |
| 2021-03-31 | $-524.47M | $332.76M | (m) | (m) | $208.84M | -157.61% |
| 2020-12-31 | $-534.14M | $298.85M | (m) | (m) | $202.33M | -178.74% |
| 2020-09-30 | $-132.64M | $261.92M | (m) | (m) | $185.11M | -50.64% |
| 2020-06-30 | $-76.48M | $251.31M | (m) | (m) | $166.17M | -30.43% |
| 2020-03-31 | $-47.42M | $264.22M | (m) | (m) | $154.33M | -17.95% |
| 2019-12-31 | $-30.57M | $245.89M | (m) | (m) | $130.83M | -12.43% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $196.56M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $172.48M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-110.76M | $146.31M | (m) | (m) | $87.94M | -75.70% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-18.38M | $71.08M | (m) | (m) | $46.74M | -25.85% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.